Pharmaceuticals, Biotechnology and Life Sciences
– Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq:…
2024 Total Revenue of $528M, Representing Significant Growth of 32% Year-Over-Year1 Strong and Growing Demand for Galafold® and Pombiliti® +…
— One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to…
Orbit Phase 3 study of setrusumab in osteogenesis imperfecta continuing to planned second interim analysis, expected in mid-2025 Alvelestat, for…
Preliminary unaudited product revenue for the fourth quarter of 2024 is expected to be approximately $63 million, up approximately 366%…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025,…
BEDMINSTER, N.J. , Jan. 10, 2025 (GLOBE NEWSWIRE) — Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) announces that on January…
WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) — Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing…
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing…
MONTREAL, Jan. 09, 2025 (GLOBE NEWSWIRE) — Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company…